These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32531869)

  • 21. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
    BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
    Bruinsma SM; Nieboer D; Roobol MJ; Bangma CH; Verbeek JFM; Gnanapragasam V; Van Hemelrijck M; Frydenberg M; Lee LS; Valdagni R; Logothetis C; Steyerberg EW;
    J Urol; 2021 Jul; 206(1):62-68. PubMed ID: 33617330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.
    Lange JM; Laviana AA; Penson DF; Lin DW; Bill-Axelson A; Carlsson SV; Newcomb LF; Trock BJ; Carter HB; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Etzioni RB
    Cancer; 2020 Feb; 126(3):583-592. PubMed ID: 31639200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
    Truong M; Slezak JA; Lin CP; Iremashvili V; Sado M; Razmaria AA; Leverson G; Soloway MS; Eggener SE; Abel EJ; Downs TM; Jarrard DF
    Cancer; 2013 Nov; 119(22):3992-4002. PubMed ID: 24006289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.
    Jain S; Loblaw A; Vesprini D; Zhang L; Kattan MW; Mamedov A; Jethava V; Sethukavalan P; Yu C; Klotz L
    J Urol; 2015 Jul; 194(1):79-84. PubMed ID: 25660208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit.
    Tomer A; Nieboer D; Roobol MJ; Steyerberg EW; Rizopoulos D
    Stat Med; 2022 May; 41(12):2115-2131. PubMed ID: 35146793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.
    Erickson AM; Luzzago S; Semjonow A; Vasarainen H; Laajala TD; Musi G; de Cobelli O; Mirtti T; Rannikko A
    Eur Urol Oncol; 2018 Sep; 1(4):268-275. PubMed ID: 31100247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
    Kato T; Matsumoto R; Yokomizo A; Tohi Y; Fukuhara H; Fujii Y; Mori K; Sato T; Inokuchi J; Hashine K; Sakamoto S; Kinoshita H; Inoue K; Tanikawa T; Utsumi T; Goto T; Hara I; Okuno H; Kakehi Y; Sugimoto M
    BJU Int; 2024 Oct; 134(4):652-658. PubMed ID: 38886979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized schedules for surveillance of low-risk prostate cancer patients.
    Tomer A; Nieboer D; Roobol MJ; Steyerberg EW; Rizopoulos D
    Biometrics; 2019 Mar; 75(1):153-162. PubMed ID: 30039528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
    Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
    Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.
    Zhao J; Liu S; Gao D; Ding S; Niu Z; Zhang H; Huang Z; Qiu J; Li Q; Li N; Xie F; Cui J; Lu J
    Oncotarget; 2017 Feb; 8(6):9935-9946. PubMed ID: 28039477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
    Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
    J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.